Morningstar

Artivion Announces Presentation of Positive New Clinical Data from NEXUS TRIOMPHE and AMDS PERSEVERE Trials at the 62nd Society of Thoracic Surgery Annual Meeting

The abstract titled "Using a Novel Hybrid Aortic Arch Prosthesis for Open Repair of Acute DeBakey Type I Dissection with Malperfusion: Two-Year Results from the PERSEVERE Trial" reports noteworthy ...
Yahoo Finance

Artivion presents double win at AATS for aortic devices

Artivion has presented new clinical data from two trials, one demonstrating better patient outcomes when using its On-X aortic valve, and another validating the safety of its AMDS hybrid prosthesis ...
Nasdaq

Artivion Announces Presentation of Late-Breaking Data from AMDS PERSEVERE Trial at the 61st Society of Thoracic Surgery Annual Meeting

Full IDE Data Set Demonstrates Sustained Benefit at One Year with Use of AMDS in Acute DeBakey Type I (ADTI) Dissections Complicated by Malperfusion Data from the trial demonstrate sustained benefit ...
Investing

Artivion reports positive clinical data from aortic arch trials

ATLANTA - Artivion, Inc. (NYSE:AORT), a $1.93 billion market cap medical device company whose shares have surged 31.86% over the past six months, announced new clinical data from two trials evaluating ...